New approaches in the diagnosis and treatment of non-alcoholic fatty liver disease.-Reference-Cited by-同舟云学术

New approaches in the diagnosis and treatment of non-alcoholic fatty liver disease.

Published:2023 Issue:2 Volume:2023 Page:12-17
ISSN:2411-1457
Container-title:Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini
language:
Short-container-title:Shidnoevr. z. vnutr. simejnoi med.

Author:

Sergienko O.I., ,Oparin A.G.,Novokhatnya А.E., ,

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver diseases: 25% of the population of European countries have signs of NAFLD, 10–20% of patients with steatosis develop an inflammatory process (non-alcoholic steatohepatitis), which, if not treated, can transform into fibrosis and cirrhosis. In most people, NAFLD is not diagnosed, prognosis is inaccurate, and there are no licensed methods of treating the disease. In this review, we discuss some recent developments in NAFLD, focusing on disease definition, diagnosis, and treatment.

Publisher

National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)

Reference35 articles.

1. 1. Spiers J, Brindley J, Li W, Alazawi W. What's new in non-alcoholic fatty liver disease?. Frontline Gastroenterology. 2022;13(e1):e102-e108. http://dx.doi.org/10.1136/flgastro-2022-102122

2. 2. Alexander M, Loomis A, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Kendrick S, Waterworth D, Sattar N, Alazawi W. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Medicine. 2018;16(1):. http://dx.doi.org/10.1186/s12916-018-1103-x

3. 3. Eslam M, Sanyal A, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, Kleiner D, Brunt E, Bugianesi E, Yki-Järvinen H, Grønbæk H, Cortez-Pinto H, George J, Fan J, Valenti L, Abdelmalek M, Romero-Gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome P, Anstee Q, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin S, Harrison S, Kawaguchi T, Wong V, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. http://dx.doi.org/10.1053/j.gastro.2019.11.312

4. 4. Kim D, Konyn P, Sandhu K, Dennis B, Cheung A, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. Journal of Hepatology. 2021;75(6):1284-1291. http://dx.doi.org/10.1016/j.jhep.2021.07.035

5. 5. Wagner R, Heni M, Tabák A, Machann J, Schick F, Randrianarisoa E, Hrabě de Angelis M, Birkenfeld A, Stefan N, Peter A, Häring H, Fritsche A. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nature Medicine. 2021;27(1):49-57. http://dx.doi.org/10.1038/s41591-020-1116-9